Clinical study of GCP-001

Clinical study of GCP-001 reagent in mammary gland tissue of subjects diagnosed with breast cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080225000

Enrollment

100

Registered

2019-12-25

Start date

2019-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

investigational material(s) Generic name etc : GCP-001 INN of investigational material : - Therapeutic category code : 746 Reagents for patho-tissue tests Dosage and Administration for Investigational

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.The Women who is 35 years or older at the time of informed consent 2Patients who have been confirmed as having breast cancer and are scheduled for surgery to remove the tumor 3.Patients who understands explanation documents of informed consent and obtained written consent prior to inclusion in the trial

Exclusion criteria

Exclusion criteria: 1.Patients who participate in other clinical trials or clinical research at the time of obtaining informed consent. 2.Others, Patients who the investigator judgs difficult to participate in this study for medical reasons.

Design outcomes

Primary

Measure	Time frame
efficacy The usefulness is evaluated by comparing the measurement results (fluorescence intensity) of GCP-001 with the results of histopathological examination using a permanent pathological specimen.	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026